T. Rowe Price Associates’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.17M | Buy |
126,366
+625
| +0.5% | +$5.8K | ﹤0.01% | 1916 |
|
|
2025
Q1 | $922K | Sell |
125,741
-513,223
| -80% | -$3.76M | ﹤0.01% | 2001 |
|
|
2024
Q4 | $5.46M | Sell |
638,964
-338,432
| -35% | -$2.89M | ﹤0.01% | 1261 |
|
|
2024
Q3 | $8.5M | Sell |
977,396
-133,058
| -12% | -$1.16M | ﹤0.01% | 1168 |
|
|
2024
Q2 | $7.6M | Buy |
1,110,454
+447,782
| +68% | +$3.06M | ﹤0.01% | 1149 |
|
|
2024
Q1 | $6.03M | Buy |
662,672
+609,328
| +1,142% | +$5.55M | ﹤0.01% | 1183 |
|
|
2023
Q4 | $238K | Buy |
53,344
+12,859
| +32% | +$57.4K | ﹤0.01% | 2472 |
|
|
2023
Q3 | $128K | Buy |
40,485
+1,846
| +5% | +$5.84K | ﹤0.01% | 2611 |
|
|
2023
Q2 | $200K | Buy |
38,639
+344
| +0.9% | +$1.78K | ﹤0.01% | 2529 |
|
|
2023
Q1 | $202K | Sell |
38,295
-3,566
| -9% | -$18.8K | ﹤0.01% | 2524 |
|
|
2022
Q4 | $118K | Buy |
41,861
+10,972
| +36% | +$30.9K | ﹤0.01% | 2681 |
|
|
2022
Q3 | $129K | Buy |
30,889
+4,981
| +19% | +$20.8K | ﹤0.01% | 2660 |
|
|
2022
Q2 | $104K | Buy |
25,908
+6,167
| +31% | +$24.8K | ﹤0.01% | 2743 |
|
|
2022
Q1 | $98K | Buy |
19,741
+6,481
| +49% | +$32.2K | ﹤0.01% | 2842 |
|
|
2021
Q4 | $92K | Sell |
13,260
-21,300
| -62% | -$148K | ﹤0.01% | 2884 |
|
|
2021
Q3 | $346K | Sell |
34,560
-100
| -0.3% | -$1K | ﹤0.01% | 2521 |
|
|
2021
Q2 | $491K | Buy |
34,660
+1,759
| +5% | +$24.9K | ﹤0.01% | 2393 |
|
|
2021
Q1 | $540K | Buy |
32,901
+6,973
| +27% | +$114K | ﹤0.01% | 2327 |
|
|
2020
Q4 | $537K | Buy |
+25,928
| New | +$537K | ﹤0.01% | 2210 |
|